The Nanomedicine@ICN2 group, established at the end of 2019, is dedicated to the development of nanomaterials and devices for therapeutic and diagnostics applications. It has strong links with the Nanomedicine Lab at the Faculty of Biology, Medicine and Health at the University of Manchester, with Prof. Kostas Kostarelos leading both teams. Graphene and 2D materials have a central role in a number of research lines carried out by the group in the context of the Graphene Flagship and beyond. The group also works on liposomes and other nanoparticle systems for various biomedical applications, ranging from cancer therapeutics to neurodegenerative disease interventions.